Insights

Rare disease focus Agios is a commercial-stage, hematology-focused biopharmaceutical company with a growing pipeline aimed at transforming rare disease treatment, presenting opportunities to target rare disease patients, payers, and specialty distributors with specialized therapies like mitapivat and cevidoplenib.

Global rights growth Recent deals expanding global rights and partnerships (cevidoplenib license, Oscotec collaboration, Avanzanite distribution in Europe/UK/Switzerland) indicate potential for channel expansion, co-promotion, and regional market entry opportunities to drive sales in new geographies.

Commercial momentum Revenue trajectory showing quarterly growth and profitability signals despite a high R&D backdrop; strong near-term upside from mitapivat in sickle cell disease and the PK activator framework, suggesting upsell opportunities with specialists and payers for expanded indications.

Strategic partnerships Active ecosystem with collaborations across biotech and contract development, plus community-focused engagement; leverage partnerships to co-market, co-develop, or access rare disease communities for faster adoption and limited competition.

Tech-enabled sales Adoption of data and analytics tools (Power BI, PostgreSQL, New Relic, CRM-ready platforms) supports targeted outreach, market analytics, and performance tracking to optimize sequencing of sales motions, payer conversations, and patient access programs.

Similar companies to Agios Pharmaceuticals

Agios Pharmaceuticals Tech Stack

Agios Pharmaceuticals uses 8 technology products and services including Power BI, Microsoft SharePoint, SurveyMonkey, and more. Explore Agios Pharmaceuticals's tech stack below.

Media & News

Agios Pharmaceuticals's Email Address Formats

Agios Pharmaceuticals uses at least 4 email formats:
Agios Pharmaceuticals Email FormatsExamplePercentage
First.Last@agios.comJohn.Doe@agios.com
94%
F.Last@agios.comJ.Doe@agios.com
3%
LastF@agios.comDoeJ@agios.com
2%
Last@agios.comDoe@agios.com
1%

Frequently Asked Questions

What is Agios Pharmaceuticals's phone number?

Minus sign iconPlus sign icon
You can contact Agios Pharmaceuticals's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Agios Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Agios Pharmaceuticals is a publicly traded company; the company's stock symbol is AGIO.

What is Agios Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's official website is agios.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Agios Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of August 2026, Agios Pharmaceuticals's annual revenue is estimated to be $25M - $50M.

What is Agios Pharmaceuticals's SIC code and NAICS code?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Agios Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of August 2026, Agios Pharmaceuticals has approximately 661 employees across 6 continents, including North America, Asia and Europe. Key team members include Chief Commercial Officer: S. H., Vice President Regulatory Affairs: L. C. and President: J. G. Explore Agios Pharmaceuticals's employee directory with LeadIQ.

What industry does Agios Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Agios Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Agios Pharmaceuticals use?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's tech stack includes Power BI, Microsoft SharePoint, SurveyMonkey, PostgreSQL, Okta, Cisco, WP Engine and New Relic.

What is Agios Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Agios Pharmaceuticals's email format typically follows the pattern of First.Last@agios.com. Find more Agios Pharmaceuticals email formats with LeadIQ.

How much funding has Agios Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of August 2026, Agios Pharmaceuticals has raised $776M in funding. The last funding round occurred on Nov 07, 2019 for $256M.

When was Agios Pharmaceuticals founded?

Minus sign iconPlus sign icon
Agios Pharmaceuticals was founded in 2008.
Agios Pharmaceuticals logo

Agios Pharmaceuticals

Pharmaceutical ManufacturingMassachusetts, United States501-1000 Employees

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company in the pharmaceutical manufacturing industry, located at 88 Sidney Street, Cambridge, Massachusetts. The company focuses on rare diseases, particularly hematology, and collaborates with patient communities to develop and deliver medicines aligned with their priorities. It aims to advance a growing pipeline by combining deep biological expertise with real-world insights, supported by an inclusive, collaborative culture. Agios has pursued licensing and collaboration arrangements, including exclusive global rights to cevidoplenib, a novel oral spleen tyrosine kinase inhibitor, and a partnership with Oscotec, as well as a distribution agreement for PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland. The company engages with regulatory processes and agencies as part of its development programs, including collaboration with the U.S. FDA on labeling and REMS materials.

Section iconCompany Overview

Phone number
Website
agios.com
SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
Stock Symbol
AGIO
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2008
Employees
501-1000

Section iconFunding & Financials

  • $776M

    Agios Pharmaceuticals has raised a total of $776M of funding over 7 rounds. Their latest funding round was raised on Nov 07, 2019 in the amount of $256M as a Post IPO Equity.

  • $25M - $50M

    Agios Pharmaceuticals's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.